Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors

Inclusion Criteria: * Patient with first liver transplantion or retransplantation since more than 6 months: with a post-transplant lapse of time of 2 to 10 years and showing one of the following adverse effects of ICN: * Renal insufficiency defined by a creatinine clearance \<50ml/mn (calculated or estimated according to the Cockcroft formula) * Arterial hypertension not controlled by an anti-hypertensive bitherapy * Diabetes mellitus (fasting glycaemia \>7.0mmol/l), whether treated or not * Neuromuscular toxicity * Immunosuppression by cyclosporine or tacrolimus and MMF * Hepatic biopsy performed within the 6 months preceding the inclusion for the patients with a post-transplant period of \<5 years and in the 12 months preceding the inclusion for patients with a post transplant period of \>5 years. Exclusion Criteria: * Acute rejection within the 6 months preceding the screening * Previous history of cortico-resistant rejection * Chronic rejection * Significant ductopenia (absence of inter-lobule biliary canals in more than 30% of the portal tracts) on the pre-screening biopsy. * Existence of a pre-transplantation diabetes mellitus. * Liver transplantation for auto-immune hepatitis or primary sclerosing cholangitis * Patients transplanted for viral C cirrhosis with reinfection lesions of the transplanted organ, rendering treatment by ribarivine + interferon conceivable in the year following inclusion. * Counter-indications to MMF (anaemia, leucopenia) * Immunosuppression by sirolimus, everolimus, azathioprine or corticoids